The clinical use of tetracycline has a long history, dating back to 1948. And Tetracycline antibiotics are sought after because they are “broad-spectrum antibiotics” that are effective against a variety of pathogens. In the late 1960s, semi-synthetic processes lead to the development of the second-generation tetracyclines, Minocycline and Doxycycline. In recent years, chemical modification of the D ring group of the tetracycline core has led to the discovery of glycylcyclines (such as Tigecycline and Eravacycline).
Omadacycline, also called PTK 0796 and Amadacycline, is a first-in-class aminomethylcycline antibiotic. Moreover, Omadacycline is a member of the tetracycline class of antibiotics. It is an intravenous and oral antibiotic therapy, approved (2018) by the US Food and Drug Administration (FDA). Omadacycline has the potential for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP) study. Importantly, Omadacycline acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. It possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria and atypical bacteria.
Omadacycline is still active against bacterial isolates with common tetracycline resistance mechanisms (such as TetK) and ribosomal protective proteins (such as TetM) and other resistance mechanisms to other antibiotic classes. In addition, Omadacycline has antibacterial efficacy in several animal models, including neutropenic murine lung infection, thigh infection, and intraperitoneal challenge model.
In general, Omadacycline is an orally active aminomethylcycline antibiotic in the tetracycline class. Omadacycline has the potential for the treatment of urinary tract infections including acute pyelonephritis and cystitis.